Efficiency of Proton pump Inhibitors in Patients with gastro-oesophageal reflux symptoms

Not Applicable

Completed

• Conditions: Gastro-oesophageal reflux disease; Digestive System; GI tract disorders

• Registration Number: ISRCTN68985072
• Lead Sponsor: Erasmus Medical Center (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-04-24
• Study Completion: 2008-10-01
• Last Update Posted: 4 October 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 415

Inclusion Criteria

1. Aged 18 years or older
2. Symptoms of GERD as determined by the GERD-Health Related Quality of Life (HRQL) questionnaire (score more than or equal to 12)
3. Informed consent

Exclusion Criteria

1. Aged under 18 years
2. Unable to fill out questionnaire
3. Previous history of upper Gastro-Intestinal (GI) tract cancer
4. Previous history of achalasia
5. Previous surgery to the oesophagus or stomach
6. Endoscopically demonstrated and histologically proven complicated reflux disease (ulcer, stricture, Barrett?s esophagus)
7. Coagulation disorder if uncorrected at the time of endoscopy
8. Use of warfarin or other anti-coagulant medication if uncorrected at the time of endoscopy
9. Liver cirrhosis
10. Pregnancy and lactation
11. Contraindications to the study medication

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Differences in the subgroups of patients with GERD symptoms in:<br> 1. Duration of PPI treatment (four versus eight weeks)<br> 2. Inflammatory reaction<br> 3. Prevalence of H. pylori<br> 4. Occurrence of symptoms<br>

Secondary Outcome Measures

Name	Time	Method
<br> Effect of PPI treatment on:<br> 1. Symptom relief<br> 2. Inflammatory reaction in the oesophagus<br>